Virpax Pharmaceuticals, Inc.: Nasdaq/NYSE listing notice — Virpax receives Nasdaq deficiency notice for delayed Q3 10-Q filing; 60 days to submit plan

Virpax Pharmaceuticals, Inc.

Nasdaq notified Virpax on Nov 16, 2023 for non-compliance due to late Q3 10-Q filing.
Delay stems from evaluating Delaware court decision in litigation with Sorrento Therapeutics and Scilex Pharmaceuticals.
Company has until Jan 16, 2024 to submit a plan; Nasdaq can extend to May 13, 2024.
Listing unaffected immediately; no guarantee of regaining compliance.

item 3.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.97

Virpax Pharmaceuticals, Inc. received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: late filing
Rules: 5250(c)(1)

Exact text from the filing

November 16, 2023, the Company received a letter from The NASDAQ Stock Market LLC (“NASDAQ”) notifying the Company that it was not in compliance with the continued listing requirements of NASDAQ Listing Rule 5250(c)(1) because its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 had not yet been filed with the Securities and Exchange Commission (“SEC”). NASDAQ Listing Rule 5250(c)(1) requires the Company to timely file all required periodic financial reports with the SEC. Under the Nasdaq rules, the Company now has 60 calendar days (until January 16, 2024) to submit a pl

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001213900-23-088069

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.